Aptevo says mipletamig combination enabled 21% of frontline AML patients to reach transplant
A filing reports that 21% of frontline AML patients advanced to stem cell transplant with the mipletamig combination.
A filing reports that 21% of frontline AML patients advanced to stem cell transplant with the mipletamig combination.